According to the PARA study from the Netherlands (Pregnancy-induced Amelioration of Rheumatoid Arthritis), antibody levels, i.e., rheumatoid factor (RF) and anti-cyclic citrullinated peptide (ACPA) do not change significantly with alterations in disease activity during and after pregnancy. This evidence concerns the gene PRTN3 and rheumatoid arthritis.